Título

ORIGINAL ARTICLE

REVISTA DE LA FACULTAD DE MEDICINA HUMANA 2021 - Universidad Ricardo Palma
DOI 10.25176/RFMH.v21i1.3194

MANAGEMENT OF GLYCEMIC CRISES IN ADULT PATIENTS WITH DIABETES MELLITUS: EVIDENCE-BASED CLINICAL PRACTICE GUIDELINE CLINICAL

MANEJO DE LAS CRISIS GLUCÉMICAS EN PACIENTES ADULTOS CON DIABETES MELLITUS: GUÍA DE PRÁCTICA CLÍNICA BASADA EN EVIDENCIAS

Helard Andrés Manrique Hurtado1,a, Fradis Eriberto Gil-Olivares2,b, Luis Castillo-Bravo3,c, Laura Perez-Tazzo2,b, Giovanny Carel Campomanes-Espinoza4,b, Karina Aliaga-Llerena2,d, José Humbert Lagos-Cabrera5,b, Alfredo Aguilar-Cartagena6,b, Guillermo E. Umpierrez7,a

1Servicio de Endocrinología, AUNA, Lima, Perú.
2Unidad de Guías de Práctica Clínica, AUNA, Lima, Perú.
3Servicio de Medicina Intensiva, AUNA, Lima, Perú.
4Servicio de Laboratorio, AUNA, Lima, Perú.
5Dirección Científica Académica, AUNA, Lima, Perú.
6Division of Endocrinology, Metabolism and Lipids, Department of Medicine, Emory University School of Medicine, Emory, Atlanta.
aEndocrinologist
bGeneral practitioner
cInternist doctor
dOncologist

ABSTRACT

Introduction: The manuscript summarizes the process of elaboration of the Clinical Practice Guide (CPG) for the management of glycemic crises in adult patients with diabetes mellitus of the AUNA Clinic Network. A multidisciplinary team of medical assistants and methodologists carried out the development of the CPG and then there was an external review by a specialist in the field. Method: The Elaboration Group of the CPG (GEG) concluded on 10 PICO questions. A systematic search for CPG, systematic reviews and primary studies was carried out to answer these PICO questions. To make recommendations we used the "GRADE-Adolopment" methodology and the guidelines of the national regulations. Results: Ten recommendations were made (nine strong and one weak), 18 points of good clinical practice and two flowcharts for management (one for diagnosis and the other for the treatment of glycemic crises), 04 consensus tables on management and 01 table for surveillance and monitoring. The topics covered by the recommendations for the management of glycemic crises were hyperglycemic crises (glycosylated hemoglobin evaluation; b-hydroxybutyrate evaluation; insulin, potassium, 0.9% sodium chloride, phosphorus, sodium bicarbonate treatments) and hypoglycemic crises (carbohydrate administration, monitoring, educational program to avoid reentry). Conclusion: This article summarizes the methodology and evidence-based recommendations of the CPG for the management of glycemic crisis in patients with diabetes mellitus in AUNA.

Key words: Diabetes mellitus, Clinical Practice Guideline, disease management, hypoglycemia, hyperglycemia (Source: MeSH MLN).

RESUMEN

Introducción: El artículo resume el proceso de elaboración de la Guía de Práctica Clínica (GPC) para el manejo de las crisis glucémicas en pacientes adultos con diabetes mellitus de la Red de Clínicas AUNA. Método: Las preguntas PICO fueron priorizadas por el Grupo Elaborador de la GPC (GEG) luego de lo cual se concluyó en trabajar 10 preguntas PICO. Para dar respuesta a las preguntas se realizó una búsqueda sistemática de GPC, revisiones sistemáticas y estudios primarios. Se utilizó la metodología “GRADE-Adolopment” y los lineamientos de la normativa nacional para la formulación de recomendaciones. Resultados: Se formularon 10 recomendaciones (nueve fuertes y una débil), 18 puntos de buena práctica clínica, dos flujogramas para el manejo (uno para el diagnóstico y el otro para el tratamiento de crisis glucémicas), 5 tablas resumen sobre el manejo y 1 tabla para la vigilancia y seguimiento. Los temas que abarcaron las recomendaciones para el manejo de las crisis glucémicas fueron: crisis hiperglucémicas (evaluación de hemoglobina glucosilada; evaluación de b-hidroxibutirato; tratamiento con insulina, potasio, cloruro de sodio 0.9%, fósforo y bicarbonato de sodio) y crisis hipoglucémicas (administración de carbohidratos, monitoreo y programa educativo para evitar el reingreso). Conclusión: El presente artículo resume la metodología y las recomendaciones basadas en evidencia de la GPC para el manejo de la crisis glucémica en pacientes con diabetes mellitus de la Red de Clínicas AUNA.

Palabras clave: Diabetes mellitus, guía de práctica clínica, manejo de la enfermedad, hipoglucemia, hiperglucemia (Fuente: DeCS – BIREME).

INTRODUCTION

Diabetes mellitus is a disease with great impact worldwide(1,2). For the year 2019, it has been estimated that 9.3% (463 million) of the world population have this disease(3). Its acute complications (hypoglycemia and hyperglycemia) are a frequent cause of admission to hospital emergency services, especially in developing countries(4-7).

In Peru, for 2015 the prevalence of diabetes mellitus was estimated between 6.1 - 7%. Within glycemic emergencies, ketoacidosis and hypoglycemia were the most common (21.6%) followed by hyperosmolar hyperglycemic state (18.2%)(5). In that year it was approved by R.M. 719-2015 / MINSA the Technical Guide: "Clinical Practice Guide for the Diagnosis, Treatment, and Control of Type 2 Diabetes Mellitus in the First Level of Care" which included some recommendations for the management of glycemic crises; However, in the study carried out by Neira-Sánchez and Germán Málaga where their quality was evaluated using the AGREE II instrument, scores of less than 60% were found in all domains (The percentage in rigor in the elaboration was 17.71%)(8,9)

During 2019, taking into account the need to have Clinical Practice Guidelines based on the best available scientific evidence for the management of glycemic crises, AUNA proposed to its Academic Scientific Directorate that, through the Unit of Clinical Practice Guidelines, lead the development of the Clinical Practice Guide (CPG) for the management of glycemic crises in adult patients with diabetes mellitus.

METHODS

The process of preparing the clinical practice guide was developed taking into account the methodological proposal "GRADE-Adolopment"(10,11) and the methodological guidelines of the national regulations(12). The GRADE-ADOLOPMENT methodology combines the advantages of formulating recommendations by adopting, adapting, and formulating de novo based on the GRADE strategy that includes, for each PICO question proposed by the panel, a summary of the evidence found (table “SoF”) and a paper discussion with a multidisciplinary team called “From evidence to recommendation” (EtD). The strategy has already been validated by the GRADE team and has been accepted in the construction of some clinical practice guidelines in different countries and organizations at the international and national levels.(13-17).

Formation of the GEG and scope of the CPG

The preparation of the CPG was carried out by the Guide Development Group (GEG). The GEG was made up of two teams: the methodological team of the CPG Unit and the team of doctors from the healthcare area of the specialties of endocrinology, internal medicine, intensive medicine, and clinical laboratory.

The GEG decided to develop a CPG that provides guidelines to healthcare professionals (medical specialists, general practitioners, and other health professionals within the scope of their competencies) for the care of adult diabetic patients in emergency services, intermediate care units, or critical care from the AUNA Network clinics.

Formulation of PICO Questions, Systematic Search and AGREE II Evaluation

The PICO questions were selected based on the GEG prioritization criteria. The team of specialists decided during the panel sessions to consider the final structure of the question. A systematic search strategy for Clinical Practice Guidelines related to the study topic was carried out in Medline databases (via Pubmed), TRIP Database, Excerpta Medica Database (EMBASE, via Ovid), Latin American and Caribbean Literature in Health Sciences. Health (LILACS) and Epistemonikos with no start date until August 07, 2019. In addition, a search was carried out in CPG compiling and compiling bodies. The methodological quality was evaluated through two steps: following pre-selection criteria and then the AGREE II tool (https://www.agreetrust.org/) was used to assess the CPGs that passed the pre-selection criteria(18-22) (Ver table 1).

Review, synthesis, and discussion of the evidence

The clinical questions that could be answered by CPG recommendations that obtained a favorable rating in the AGREE II instrument (see table 1) were submitted to the GEG for discussion and it was decided whether or not they would be updated. For each of the other questions prioritized by the specialists, a systematic search for evidence was developed. In the case of questions answered by a CPG, in which some modification had been made in its structure, the adaptation of the search strategies was considered, while in the case of questions that had not been answered by any CPG, the procedure was to do a de novo search. In all cases, the review of the evidence found followed a process by independent peers that began with a reading phase of titles and abstracts, followed by a full-text reading phase of the potentially relevant citations identified in the previous phase. Any discrepancies were resolved by consensus during the GEG sessions.

Table 1. Evaluación de calidad metodológica de las GPC de cáncer de mama usando la herramienta AGREE II

Clinical Practice Guide

Domain 1: Scope and objective

Domain 2: Stakeholder involvement

Domain 3: Rigor in Crafting

Domain 4: Clarity of presentation

Domain 5: Applicability

Domain 6: Editorial independence

Overall evaluation

 

1

Canadian Diabetes Association Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.

76%

85%

71%

96%

61%

86%

78%

 

2

American Diabetes Association Standards of Medical Care in Diabetes—2019

92%

75%

83%

89%

81%

92%

92%

 

3

Cenetec Diagnóstico y tratamiento de la Cetoacidosis Diabética en niños y adultos

94%

72%

65%

56%

60%

63%

75%

 

4

Cenetec Diagnóstico y tratamiento del Estado Hiperglucémico Hiperosmolar en adultos con Diabetes Mellitus tipo 2

100%

81%

71%

58%

63%

71%

75%

 

5

NICE Type 1 diabetes in adults: Diagnosis and management

75%

81%

71%

58%

67%

96%

83%

 
Fuente: Elaboracion Propia


Formulation and Grading of Recommendations

The formulation of the recommendations was carried out during the sessions of the GEG after the review and analysis of the evidence found (see tables 2 and 3). For the grading of the recommendation (strength and direction), the GRADE system (https://gradepro.org/) was used, which provides 4 criteria for grading the recommendations based on the quality of the evidence, balance between benefits and risks, values and preferences as well as costs and use of resources: strong in favor (The desirable consequences clearly outweigh the undesirable consequences. It is recommended to do so), Weak in favor (The desirable consequences probably outweigh the undesirable consequences. It is suggested to do so), Strong against (The undesirable consequences clearly outweigh the desirable consequences. It is not recommended to do so), Weak against (The undesirable consequences probably outweigh the desirable consequences. It is not suggested to do so) and Good Clinical Practice (Recommended practice, based on clinical experience and / or studies not systematically evaluated by the GEG).

Table 2. Recommendations made by the GEG in cases of hyperglycemic crisis with strength and direction of the recommendation

Recommendations

Strength and direction

Certainty in the evidence

 

 

1

Evaluation of glycosylated Hb in diabetic patients diagnosed with hyperglycemia is not suggested for acute management.

Conditional against

Very low (⊕⊝⊝⊝)

 

 

 

 

2

After the acute management of diabetic patients with hyperglycemia, perform a glycosylated Hb analysis for subsequent follow-up.

BPC

 

 

 

3

The evaluation of B-hydroxybutyrate in the blood in diabetic patients is recommended for the diagnosis of CAD.

Strong for

Very low (⊕⊝⊝⊝)

 

 

 

 

4

Consider periodic monitoring (every 4 hours until resolution) of B-hydroxybutyrate in the blood of diabetic patients found with CAD in the acute phase.

BPC

 

 

 

5

In diabetic patients with b-hydroxybutyrate> = 1 should be considered to rule out CAD.

BPC

 

 

 

6

It is recommended to start insulin infusion doses at 0.05 - 0.1 U / Kg /

Strong for

Very low (⊕⊝⊝⊝)

 

 

 

 

7

Adjust the dose to 25% while achieving an average decrease of 50 mg / dL per hour.

BPC

 

 

 

8

Maintain glucose values between 140 - 180 mg / dL in diabetic patients with hyperglycemia in critical or non-critical condition.

BPC

 

 

 

9

It is recommended in adult diabetic patients with hyperglycemic crisis (CAD / EHH) with marked hypokalemia (serum potassium <3.3 mmol / L), add potassium at a dose of 10 - 20 mmol / L

Strong for

Very low (⊕⊝⊝⊝)

 

 

 

 

10

Avoid the administration of Potassium, if the concentration of K is> 5.2 mEq / l.

 

BPC

 

 

 

11

In adult diabetic patients with hyperglycemic crisis (CAD / HD) with normokalemia or mild hypokalemia (serum potassium between 3.3 mmol / L to 5 mmol / L, start intravenous potassium administration at concentrations of 10 - 20 mmol / L, at a maximum range 20 mmol / h) once urine output is restored. Taking precaution if the patient has kidney failure.

BPC

 

 

 

12

It is recommended in adult diabetic patients with hyperglycemic crisis (CAD / EHH), initially administer 0.9% NaCl at 1000 ml / h until hypovolemic shock is corrected, then 0.9% NaCl at 500 ml / h for 4 hours and continue at 250 mL / h.

Strong for

Very low (⊕⊝⊝⊝)

 

 

 

 

13

In adult diabetic patients with hyperglycemic crisis (CAD / EHH), carry out continuous monitoring of diuresis (if necessary, place a urinary catheter).

BPC

 

 

 

14

Phosphorus replacement is not recommended in adult diabetic patients with hyperglycemic crisis (CAD / EHH) and non-severe hypophosphatemia.

Strong agains

Very low (⊕⊝⊝⊝)

 

 

 

 

15

In cases where hypophosphatemia is severe (<1 mg / dL (0.32 mmol / l), consider its replacement.

BPC

 

 

 

16

In adult diabetic patients with hyperglycemic crisis (CAD / EHH) and hypophosphatemia, monitor serum phosphorus levels.

BPC

 

 

 

17

The administration of sodium bicarbonate is not recommended in adult diabetic patients with CAD with pH ≥ 6.9

Strong against

Very low (⊕⊝⊝⊝)

 

 

 

 

18

It is recommended in adult diabetic patients who present severe CAD with pH <6.9 or in shock, the administration of 50 mmol of sodium bicarbonate in 200 mL of normal saline for one hour and continue every 1 - 2 hours until the pH is ≥ 6.9.

Strong for

Very low (⊕⊝⊝⊝)

 

 

 

 

19

In adult diabetic patients presenting with severe CAD with pH <6.9 or in shock who are replaced with sodium bicarbonate, monitor serum potassium.

BPC

 

 

 

 

 

 

 

 

 
Fuente: Elaboracion Propia

Table 3. Recommendations made by the GEG in cases of hypoglycemia with strength and direction of the recommendation.

Recommendations

Strength and Direction

Certainty in the evidence

1

Treat severe hypoglycemia in a conscious person in the emergency area by orally ingesting 20 g of carbohydrates, preferably as glucose tablets or equivalent (eg dilute a tablespoon of sugar in 1 glass with water or observe the equivalent in the tables of nutritional balance of the products to be consumed)

BPC

 

2

Check blood glucose values every 15 minutes and ingest another 20 g of glucose if blood glucose remains <4.0 mmol / L (72 mg / dL).

BPC

 

3

Treat severe hypoglycemia in an unconscious person by intravenous administration of 25 g (4 ampoules of 33% dextrose) of glucose administered during the first 3 minutes.

BPC

 

4

In patients with severe hypoglycemia, consider a residence time of at least 24 hours.

BPC

 

5

In patients with severe hypoglycemia associated with complications, consider that the hospital stay could be longer.

BPC

 

6

In patients with severe hypoglycemia consider monitoring capillary blood glucose every 1-2 hours for the first 6 hours.

BPC

 

7

IT IS RECOMMENDED to standardize an educational program aimed at the patient and / or family while maintaining general glycemic control aimed at avoiding readmission for hypoglycemia.

Source in favor

Very low (⊕⊝⊝⊝)

8

Include a psycho-behavioral therapeutic intervention directed towards patients if readmissions are recurrent (> 3 times a year).

BPC

 

Source: Self made.


Conflicts of Interest of Participants in the GEG

To ensure the integrity and public trust in the activities of the GEG; each one declared their conflicts of interest according to the Form for Declaration of Conflicts of Interest of the Technical Document: Methodology for the Preparation of Clinical Practice Guidelines of the Ministry of Health.

External Review

The CPG was evaluated by an endocrinologist specialized in the subject with expertise in the development of clinical practice guidelines with GRADE methodology. You were asked to declare if you have any conflict of interest to express an opinion on any of the issues reviewed within the CPG. After the review, a tele-meeting was held to discuss the suggestions submitted by the external reviewer and conclude the final version of the clinical practice guideline.

Implementation, monitoring of compliance with Recommendations, and updating of the CPG

The CPG was socialized through internal meetings and space was created on the institutional website: https://clinicadelgado.pe/guias-de-practica-clinica/. Through it, you can access the 2 versions of the CPG (long version and summary version).

To follow up on the recommendations, it was decided to choose key recommendations on which the indicators were built (see table 3).Said indicators would be evaluated at 06 months and one year after the approval of this CPG.

It was decided at the GEG meeting that the CPG update be carried out within a period of 3 years from the date of its publication, or when relevant information is identified that may modify the meaning of the clinical recommendations included. To identify relevant information, an update of the search strategies for the recommendations will be developed every six months.

RECOMMENDATIONS

Hyperglycemic Crises
Seven questions were developed regarding hyperglycemic crises. Two tables were prepared, the first to summarize the diagnosis and severity of hyperglycemic crises and the second to establish criteria for electrolyte administration (see table 4 and table 5). Further; Two figures were prepared, 1 figure that included the diagnosis of hyperglycemic crises and 1 figure that included the treatment of hyperglycemic crises (see figure 1 y figure 2)

Hypoglycemia
3 questions were raised regarding hypoglycemia. A table was prepared that summarizes the diagnosis and severity of hypoglycemia (see Table 6). Further; a figure was prepared that included a summary of the diagnosis and management of hypoglycemia (see figure 1).

Table 5. Criteria for the diagnosis and severity of diabetic ketoacidosis and hyperosmolar hyperglycemic state in diabetic patients.

Criterios Diagnósticos

Cetoacidosis Diabética

Estado Hiperosmolar

Mild (Plasma Glucose >=250 mg/dl)

Moderate (Plasma Glucose >=250 mg/dl)

Severe (Plasma Glucose >=250 mg/dl)

(Plasma Glucose >=600 mg/dl)

Arterial Ph

7.25-7.30

7.00 a <7.25

<7.00

>7.30

Anion Gap

>10

>12

>12

Variable

Blood Osmolarity

Variable

Variable

Variable

>320 mOsm/Kg

Bicarbonate of Blood

15-18 mEq /L

10-<15 mEq /L

<10 mEq /L

>18 mEq /L

Ketonic Bodies in Blood / Urine

Positive

Positive

Positive

Slightly positive

Neurological Status

Alert

Alert/Sleep

Stupor / Coma

Stupor / Coma

Source: Prepared based on the translated criteria of Kitabchi AE, Umpierrez GE. Hyperglycemic crises in adult patients with diabetes. ADA. 2009; 32 (7): 1336.

Table 6. Criteria for the administration of electrolytes (potassium, phosphorus and bicarbonate) in diabetic ketoacidosis and hyperosmolar hyperglycemic state.

Diagnostic criteria

Standard to start administration

Diabetic cetoacidosis

Hyperosmolar hyperglycemic state

Match

Consider phosphate replace-ment if serum phosphate <1 mg / dL (0.32 mmol / L) (also consider phosphate replacement in patients with cardiac dysfunction, anemia, or respiratory distress)

Limit phosphorus replacement to persistent hypophosphatemia (after the acute phase has elapsed).

Potassium

If K ≥ 5.2 mEq / L (5.2 mmol / L), no replacement but continuous monitoring every 2 hours.

Potassium is usually elevated, generally due to extracellular change caused by insulin deficiency, hypertonicity, and acidemia.

If K ≥ 3.3 mEq / L and K <5.2 mEq / L (5.2 mmol / L); replenish potassium as recommended

If K <3.3 mEq / L (3.3 mmol / L) re-places potassium earlier as recommended before starting insulin therapy.

Baking soda

Replenish usually if the pH is less than 6.9. (Consider replacement in special conditions such as vascular collapse or cardiac arrhythmias)

It does not require

Source: Elaborated based on the translated criteria Kitabchi AE, Umpierrez GE. Hyperglycemic crises in adult patients with diabetes. ADA. 2009; 32 (7): 1336.

Table 7. Criteria for the diagnosis and severity of hypoglycemia in diabetic patients.

Mild (level 1) Moderate (level 2) Severe (level 3)
Autonomic signs: tremor, palpitations, sweating, anxiety, nausea pre-sent and / or Autonomic and neuroglycopenic symptoms (Difficulty concentrating,Confusion, weakness, drowsiness, vision changes, headache, dizziness) present and / or It could be unconscious.Severe event characterized by men-tal and physical alterations and / or
Glucose minus 70 mg / dL and ≧ 54 mg / dL. (3.9 mmol / L) Glucose <54 mg / dL. (3 mmol / L) Glucose usually less than 50 mg / dL. (2.8 mmol)
Source: Elaborado en base a los criterios traducidos de CJD “Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada y los criterios traducidos de ADA. “American Diabetes Association Standards of Medical Care in Diabetes”—2019”.

Figure 1. Flow chart for the diagnosis of glycemic crisis in diabetic patients.


Figure 2. Flow chart for the treatment of glycemic crises in diabetic patients.


Authorship contributions: The authors participated in the genesis of the idea, project design, data collection and interpretation, analysis of results and preparation of the manuscript of this research work.
Funding Sources: : The development of the Clinical Practice Guide up to the publication stage was financed by the Academic Scientific Directorate of AUNA (Peruvian Network of Clinics and Health Centers - https://auna. pe/).
Conflicts of interest: The authors declare no conflict of interest.
Received: December 1, 2020
Approved: January 6, 2021


Correspondence: Fradis Gil Olivares.
Address: Av. Arequipa 1388. Dpto 206-A., Lima-Perú.
Telephone: 999141011
Email: fradisgl@gmail.com


REFERENCES

    1. Muka T, Imo D, Jaspers L, Colpani V, Chaker L, van der Lee SJ, et al. The global impact of non-communicable diseases on healthcare spending and national income: a systematic review. Eur J Epidemiol. 2015;30(4):251-277. DOI: 10.1007/s10654-014-9984-2
    2. Seuring T, Archangelidi O, Suhrcke M. The Economic Costs of Type 2 Diabetes: A Global Systematic Review. Pharmacoeconomics. 2015;33(8):811-831. DOI: 10.1007/s40273-015-0268-9.
    3. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843. DOI: 10.1016/j.diabres.2019.107843.
    4. McNaughton CD, Self WH, Slovis C. Diabetes in the Emergency Department: Acute Care of Diabetes Patients. Clin Diabetes. 2011;29(2):51-59. Disponible en: https://doi.org/10.2337/diaclin.29.2.51.
    5. Villena JE. Diabetes Mellitus in Peru. Annals of Global Health. 2015;81(6):765-775. Disponible en: https://doi.org/10.1016/j.aogh.2015.12.018.
    6. Jawaid A, Sohaila A, Mohammad N, Rabbani U. Frequency, clinical characteristics, biochemical findings and outcomes of DKA at the onset of type-1 DM in young children and adolescents living in a developing country – an experience from a pediatric emergency department. J Pediatr Endocrinol Metab. 2019;32(2):115-119. DOI: 10.1515/jpem-2018-0324.
    7. Iloh GUP, Amadi ANk. Epidemiology of Diabetic Emergencies in the Adult Emergency Department of a Tertiary Hospital in South-Eastern Nigeria. Int J Trop Dis Health. 2018;1-10. Disponible en: https://doi.org/10.9734/IJTDH/2018/28806.
    8. MINSA. Guía Técnica: «Guía de Práctica Clínica para el diagnóstico, tratamiento y control de la diabetes mellitus tipo 2 en el primer nivel de atención». 2015. Disponible en: https://cdn.www.gob.pe/uploads/document/file/194552/193275_RM_719-2015 MINSA.pdf20180904-20266-1tlkwzr.pdf.
    9. Neira-Sanchez ER, Málaga G. ¿Son las guías de práctica clínica de hipertensión arterial y diabetes mellitus tipo 2 elaboradas por el MINSA, confiables? Rev Peru Med Exp Salud Pública. 2016; 33(2):377. Disponible en: https://rpmesp.ins.gob.pe/index.php/rpmesp/article/view/2093/2254.
    10. Schünemann HJ, Wiercioch W, Brozek J, Etxeandia-Ikobaltzeta I, Mustafa RA, Manja V, et al. GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT. J Clin Epidemiol. 2017;81:101-110. DOI: https://doi.org/10.1016/j.jclinepi.2016.09.009.
    11. Tugwell P, Knottnerus JA. Adolopment – a new term added to the Clinical Epidemiology Lexicon. J Clin Epidemiol. 2017;81:1-2. DOI: 10.1016/j.jclinepi.2017.01.002.
    12. Ministerio de Salud. Norma Técnica de Salud para la elaboración y Uso de Guías de Práctica Clínica. 2015. Disponible en: http://bvs.minsa.gob.pe/local/MINSA/3300.pdf.
    13. Wong CHL, Wu IXY, Adams J, Steel A, Wardle J, Wu JCY, et al. Development of Evidence-Based Chinese Medicine Clinical Service Recommendations for Cancer Palliative Care Using Delphi Approach Based on the Evidence to Decision Framework. Integr Cancer Ther. 2020;19:1-13. DOI: 10.1177/1534735420940418
    14. Kallenbach M, Conrad S, Hoffmann F, Matthias K, Gartlehner G, Langer G, et al. GRADE Evidence-to-Decision-Tabellen für die Übernahme, Anpassung und De-novo-Entwicklung von vertrauenswürdigen Empfehlungen: GRADE-ADOLOPMENT. Z Für Evidenz Fortbild Qual Im Gesundheitswesen. 2019;144(145):90-99. Disponible en: https://doi.org/10.1016/j.zefq.2019.06.001
    15. Darzi A, Harfouche M, Arayssi T, Alemadi S, Alnaqbi KA, Badsha H, et al. Adaptation of the 2015 American College of Rheumatology treatment guideline for rheumatoid arthritis for the Eastern Mediterranean Region: an exemplar of the GRADE Adolopment. Health Qual Life Outcomes. 2017;15(1):183. Disponible en: https://hqlo.biomedcentral.com/articles/10.1186/s12955-017-0754-1.
    16. Timana-Ruiz R. Desarrollo de Guías de Práctica Clínica en el Seguro Social del Perú. Rev Cuerpo Méd HNAAA. 2019;12(2):95-96. Disponible en: https://doi.org/10.35434/rcmhnaaa.2019.122.503.
    17. Cabrera PA, Pardo R. Review of evidence based clinical practice guidelines developed in Latin America and Caribbean during the last decade: an analysis of the methods for grading quality of evidence and topic prioritization. Glob Health [Internet]. 19 de febrero de 2019 [citado 26 de agosto de 2020];15. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380043.
    18. Diabetes Canada Clinical Practice Guidelines Expert Committee. Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. 2018;42(1):320-325. Disponible en: http://guidelines.diabetes.ca/cpg.
    19. American Diabetes Association. American Diabetes Association’s Standards of Medical Care in Diabetes—2019. Clin Diabetes. 2019;37(1):11-34. Disponible en: https://doi.org/10.2337/cd18-0105.
    20. NICE. Type 1 diabetes in adults: diagnosis and management. 2015. Disponible en: https://www.nice.org.uk/guidance/ng17.
    21. CENETEC. Dagnóstico y Tratamiento de la cetoacidosis diabética en niños y adultos. 2016. Disponible en: http://www.cenetec-difusion.com/CMGPC/SS-227-09/ER1.pd.
    22. CENETEC. Diagnóstico y tratamiento del estado hiperglucémico hiperosmolar en adultos con diabetes mellitus tipo 2. 2016. Disponible en: http://www.cenetec-difusion.com/CMGPC/SS-227-09/ER1.pdf
    23. Liang K, Sun Y, Li W, Zhang X, Li C, Yang W, et al. Diagnostic efficiency of hemoglobin A1c for newly diagnosed diabetes and prediabetes in community-based Chinese adults aged 40 years or older. Diabetes Technol Ther. diciembre de 2014;16(12):853-857. DOI: 10.1089/dia.2014.0157
    24. Yang C, Liu Y, Li X, Liang H, Jiang X. Utility of hemoglobin A1c for the identification of individuals with diabetes and prediabetes in a Chinese high risk population. Scand J Clin Lab Invest. 2012;72(5):403-409. DOI: 10.3109/00365513.2012.689324
    25. Guo W, Zhou Q, Jia Y, Xu J. Increased Levels of Glycated Hemoglobin A1c and Iron Deficiency Anemia: A Review. Med Sci Monit Int Med J Exp Clin Res. 2019;25:8371-8. DOI: 10.12659/MSM.916719.
    26. Greci LS, Kailasam M, Malkani S, Katz DL, Hulinsky I, Ahmadi R, et al. Utility of HbA1c Levels for Diabetes Case Finding in Hospitalized Patients With Hyperglycemia. Diabetes Care. 2003;26(4):1064-1068. DOI: 10.2337/diacare.26.4.1064
    27. Su Y-W, Hsu C-Y, Guo Y-W, Chen H-S. Usefulness of the plasma glucose concentration-to-HbA1c ratio in predicting clinical outcomes during acute illness with extreme hyperglycaemia. Diabetes Metab. 2017;43(1):40-47. DOI: 10.1016/j.diabet.2016.07.036
    29. Brooke J, Stiell M, Ojo O. Evaluation of the Accuracy of Capillary Hydroxybutyrate Measurement Compared with Other Measurements in the Diagnosis of Diabetic Ketoacidosis: A Systematic Review. Int J Environ Res Public Health. 2016;13(9):837. DOI: 10.3390/ijerph13090837.
    30. Klocker AA, Phelan H, Twigg SM, Craig ME. Blood β-hydroxybutyrate vs. urine acetoacetate testing for the prevention and management of ketoacidosis in Type 1 diabetes: a systematic review. Diabet Med. 2013;30(7):818-824. DOI: 10.1111/dme.12136.
    31. Prisco F, Picardi A, Iafusco D, Lorini R, Minicucci L, Martinucci ME, et al. Blood ketone bodies in patients with recent-onset type 1 diabetes (a multicenter study). Pediatr Diabetes. 2006;7(4):223-228. DOI: 10.1111/j.1399-5448.2006.00187.x.
    32. Laffel LMB, Wentzell K, Loughlin C, Tovar A, Moltz K, Brink S. Sick day management using blood 3-hydroxybutyrate (3-OHB) compared with urine ketone monitoring reduces hospital visits in young people with T1DM: a randomized clinical trial. Diabet Med. 2006;23(3):278-284. DOI: 10.1111/j.1464-5491.2005.01771.x.
    33. Vanelli M, Chiari G, Capuano C, Iovane B, Bernardini A, Giacalone T. The direct measurement of 3-beta-hydroxy butyrate enhances the management of diabetic ketoacidosis in children and reduces time and costs of treatment. Diabetes Nutr Metab. 2003;16(5-6):312-316. Disponible en: https://pubmed.ncbi.nlm.nih.gov/15000443/
    34. Noyes KJ, Crofton P, Bath LE, Holmes A, Stark L, Oxley CD, et al. Hydroxybutyrate near-patient testing to evaluate a new end-point for intravenous insulin therapy in the treatment of diabetic ketoacidosis in children. Pediatr Diabetes. 2007;8(3):150-156. DOI: 10.1111/j.1399-5448.2007.00240.x.
    35. Andrade-Castellanos CA, Colunga-Lozano LE, Delgado-Figueroa N, Gonzalez-Padilla DA. Subcutaneous rapid-acting insulin analogues for diabetic ketoacidosis. Cochrane Metabolic and Endocrine Disorders Group, editor. Cochrane Database Syst Rev [Internet]. 21 de enero de 2016 [citado 20 de febrero de 2020]; Disponible en: http://doi.wiley.com/10.1002/14651858.CD011281.pub2
    36. Firestone RL, Parker PL, Pandya KA, Wilson MD, Duby JJ. Moderate-Intensity Insulin Therapy Is Associated With Reduced Length of Stay in Critically Ill Patients With Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic State: Crit Care Med. 2019;47(5):700-705. DOI: 10.1097/CCM.0000000000003709
    37. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic Crises in Adult Patients With Diabetes. Diabetes Care. 2009;32(7):1335-1343. Disponible en: https://doi.org/10.2337/dc09-9032.
    38. Chiasson J-L, Aris-Jilwan N, Bélanger R, Bertrand S, Beauregard H, Ekoé J-M, et al. Diagnosis and treatment of diabetic ketoacidosis and the hyperglycemic hyperosmolar state. CMAJ Can Med Assoc J J Assoc Medicale Can. 2003;168(7):859-866. Disponible en: https://europepmc.org/article/med/12668546.
    39. Adrogué HJ. Salutary Effects of Modest Fluid Replacement in the Treatment of Adults With Diabetic Ketoacidosis: Use in Patients Without Extreme Volume Deficit. JAMA. 1989;262(15):2108. DOI: 10.1001/jama.1989.03430150076029.
    40. Fein IA. Relation of Colloid Osmotic Pressure to Arterial Hypoxemia and Cerebral Edema During Crystalloid Volume Loading of Patients with Diabetic Ketoacidosis. Ann Intern Med. 1982;96(5):570. DOI: 10.7326/0003-4819-96-5-570.
    41. Fisher JN, Kitabchi AE. A Randomized Study of Phosphate Therapy in the Treatment of Diabetic Ketoacidosis*. J Clin Endocrinol Metab. 1983;57(1):177-80. DOI: 10.1210/jcem-57-1-177.
    42. Chua H, Schneider A, Bellomo R. Bicarbonate in diabetic ketoacidosis - a systematic review. Ann Intensive Care. 2011;1(1):23. DOI: 10.1186/2110-5820-1-23.
    43. Tan HK, Flanagan D. The impact of hypoglycaemia on patients admitted to hospital with medical emergencies. Diabet Med. 2013;30(5):574-580. DOI: 10.1111/dme.12123.
    44. Naylor M. Comprehensive Discharge Planning for the Hospitalized Elderly: A Randomized Clinical Trial. Ann Intern Med. 1994;120(12):999. Disponible: https://www.diagnostic.grifols.com/en/clinical-diagnostics?gclid=CjwKCAiA_eb-BRB2EiwAGBnXXgAc3MBX4jP Ktm4_SUbMncfo6JEzVAoKK6by9weJIaNpTkOuVwmKhoCJ_gQAvD_BwE.
    45. Dai Y-T, Chang Y, Hsieh C-Y, Tai T-Y. Effectiveness of a pilot project of discharge planning in Taiwan. Res Nurs Health. 2003;26(1):53-63. DOI: 10.1002/nur.10067.
    46. Jayakody A, Bryant J, Carey M, Hobden B, Dodd N, Sanson-Fisher R. Effectiveness of interventions utilising telephone follow up in reducing hospital readmission within 30 days for individuals with chronic disease: a systematic review. BMC Health Serv Res [Internet]. 18 de agosto de 2016 [citado 20 de febrero de 2020]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4990979/
    47. Thompson CJ, Cummings F, Jung RT, Newton RW. The effects of an integrated education programme on the management of diabetic ketoacidosis. Pract Diabetes Int. 1995;12(5):235-237. Disponible en: https://doi.org/10.1002/pdi.1960120518.
    48. Cox DJ, Kovatchev B, Kovatchev B, Koev D, Koeva L, Dachev S, et al. Hypoglycemia anticipation, awareness and treatment training (HAATT) reduces occurrence of severe hypoglycemia among adults with type 1 diabetes mellitus. Int J Behav Med. 2004;11(4):212-218. DOI: 10.1207/s15327558ijbm1104_4.

http://www.scielo.org.pe/scielo.php?script=sci_serial&pid=2223-2516&lng=en&nrm=iso


¿Quieres dejar tu comentario o sugerencia sobre este artículo?

---> CLICK AQUI <---